Creative Biolabs Boosts Offerings with Enhanced Non-IgG Antibody Engineering Service and More
Mar 24, 2023
New York City, New York Mar 24, 2023 (Issuewire.com) - Antibody development research has long been an exciting and rapidly advancing field with great promise for improving human health. And the advance of antibody engineering technology is expected to drive significant advances in the development of innovative therapies and cures. As one of the first-class biotech manufacturers, Creative Biolabs has taken a deep dive into the technology innovation and announced updates to three of its offerings: non-IgG therapeutic antibody engineering, autoantibody profiling, and ribosomal marker antibody development.
With a team of scientists focusing on unveiling more potential of non-IgG antibodies, including IgA, IgM, and IgE, the antibody engineering service has recruited an extensive range of strategies, which can be flexibly assembled to serve specific applications and purposes.
The expert team will help evaluate the existing project or design a custom one based on the technology platform covering chimeric non-IgG antibody, humanized non-IgG antibody, glycosylated non-IgG antibody, bi-specific non-IgG antibody, half-life extension, antibody isotype switching, and non-IgG antibody drug conjugation.
The natural autoantibody profiling service has been updated to serve clients with autoantigen microarray and autoantibody microarray, with enhanced efficiency and reproducibility for clients' research on the identification of biomarkers and the prediction and diagnosis of diseases.
The autoantibody microarray is one of the hottest services, which has proved its capability based on the previous cases on cIgG, IgM, IgA and IgE autoantibodies from serum or other body fluids. While the newly updated autoantigen microarray features high throughput, load, and sensitivity, with each slide processing up to 15 samples (little samples are required with only 10ul needed).
With complete hardware equipment, analysis tools, and data analysis charters, the professional bioinformatics analysis technical team introduces ribosomal maker antibody development service for the study of ribosome dynamics and morphology.
"Currently, antibody drugs have grown to be the dominant products in the biopharmaceutical market for the treatment of many diseases. To fully serve pharmaceutical companies' demand for high quality antibody products and services, we keep updating our offering to go wide and deep, hoping to help our clients make informed decisions and setting the right groundwork to succeed," said a scientist working at Creative Biolabs.
Creative Biolabs' efficient, cost-effective solutions will usher clients' projects to move at the speed of oncology with an integrated approach to development.
About Creative Biolabs
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents, including the Phage Display Platform, Membrane Protein Platform, Hyperdoma Platform, and B-Cell Sorting Platform. The unmatched range of one-stop antibody development services covers the whole workflow from antibody discovery and engineering to bio-manufacturing.
Source :Creative Biolabs
This article was originally published by IssueWire. Read the original article here.
More News
Tesla Debuts 2026 Roadster ‘Flying’ Electric Sports Car
Elon Musk’s company and other automakers, like Jaguar and Bentley, are trying to sell very expensive electric cars to people who usually prefer gasoline-fueled luxury and performance.
Trump Hasn’t Lowered Drug Prices for These Voters
President Trump has been promoting his efforts to reduce drug prices, but many Americans have not seen relief from rising costs for prescriptions and insurance premiums.
Fuel costs squeezing margins for some businesses
Diesel recently topped £2 per litre and there is concern that a duty freeze will not go far enough.
'TV and cheap booze' blamed for landlord quitting
Lincolnshire has lost 27% of its pubs and bars since 2009 and some are calling on the government to act against cheap supermarket booze.
Ship attack reports near Hormuz reach record high as oil exports slow
BBC Verify analysis of data from a UK maritime agency shows 12 vessels were struck in a week.
Netflix Replaces Bela Bajaria as Chief Content Officer
Peter Rice, a former executive at Disney and Fox, will take over from Bela Bajaria, who had held the job since 2023.
Living with a stink? Technology might help
Smells from rubbish dumps and industrial facilities are being more carefully monitored.
I find it quite demoralising in store - why I do all my shopping online
After Primark announced plans for home delivery, we hear from women who never go into clothes stores.
Gulf Oil Is Still Flowing Despite a Surge in Attacks on Ships
Shipping operators are braving the Strait of Hormuz, but the risks are high and transportation costs have skyrocketed.
Tech Stocks Drop Further Amid Doubts Over AI Spending
Tech stocks plunged before reversing course, as concerns over soaring A.I. spending and stubborn inflation fueled a sell-off.
'I'd spend $1,000 on a wedding present'
New Yorkers share how much they spend on a wedding gift - and how they decide.
Homeownership Drifts Further Out of Reach as Mortgage Rates Rise
Mortgage rates have pushed above 7 percent and home prices remain elevated, hurting the prospects of would-be buyers.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.